Evidence map›Paper›PMID 41371906›Full record

ArticleJournal for immunotherapy of cancer2025

Patterns of immune-related adverse events and treatment responses in adolescents and young adults with melanoma during initial and rechallenge immune checkpoint inhibitor therapy.

Jiasen He, Ida N John, Mianen Sun, Clark R Andersen, Yinghong Wang, Michael Roth, Jennifer McQuade

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jiasen HePediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0001-7479-4315
Ida N JohnDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mianen SunDivision of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Clark R AndersenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yinghong WangGastroenterology, Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID http://orcid.org/0000-0002-5148-6130
Michael RothPediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jennifer McQuadeDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA jmcquade@mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) are increasingly used in adolescents and young adults (AYAs) with cancer; however, data on treatment response, the frequency and pattern of immune-related adverse events (irAEs), and the feasibility of ICI rechallenge after irAEs are limited.

methodsThis retrospective study included 136 AYAs (80 males and 56 females) who received ICI therapy for melanoma at our institution from 2013 to 2023. We documented the initial ICI treatment and ICI rechallenge, along with associated irAEs and treatment responses. Kaplan-Meier plots were used to analyze overall survival (OS) and progression-free survival.

resultsAt ICI initiation, the median age was 33 (range, 15-39) years, and most patients had stage III or IV disease (93%) and

conclusionsAYA patients receiving ICI therapy for melanoma had high incidence of colitis and hepatitis and favorable survival. Initial and rechallenge ICI therapy had similar patterns of irAE severity and efficacy. Colitis and hepatitis were associated with improved OS.

Indexed as

Drug-Related Side Effects and Adverse ReactionsImmune Checkpoint InhibitorsMelanomaAdolescentAdultFemaleHumansMaleRetrospective StudiesYoung AdultImmune Checkpoint InhibitorsImmune Checkpoint InhibitorsImmune related adverse event - irAEMelanomaSurvivorship

Identifiers

PMID41371906
PMCPMC12699720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.